This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
A study led by the ITACA Institute of the Universitat Politècnica de València, with the participation of the Institut Català d'Oncologia (ICO), the Institut Investigació Germans Trias I Pujol (IGTP) and the Hospital Clinic de Barcelona, opens up a novel approach for improving personalized treatments for patients with glioblastoma, one of the most aggressive types of cancer in existence today.
The FDA is mandating that CAR T cell therapies have a new warning detailing the potential danger, though it still says their benefits outweigh the risks.
Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumor drugs as well as chemotherapy, a new trial has found.